Q3 Earnings Estimate for RAPP Issued By HC Wainwright

Key Points

• HC Wainwright projects continued losses for Rapport Therapeutics, estimating a Q3 2026 loss of $1.36 per share and a FY2026 loss of $4.51 per share, with losses expected to remain substantial through 2030.
• Rapport’s latest quarterly results missed expectations, reporting a $1.19-per-share loss versus the $1.12 consensus estimate. Wall Street Zen downgraded the stock to “Sell,” although the broader analyst consensus remains “Moderate Buy” with a $57.86 target price.
• RAPP opened at $45.49 and remains near its 12-month high of $48.00, with a $2.18 billion market capitalization; company insiders own 12.48% of the shares, while recent insider transactions included sales by the CEO and a major shareholder.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Investment analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Rapport Therapeutics in a note issued to investors on Thursday, August 6th. HC Wainwright analyst D. Tsao forecasts that the company will earn ($1.36) per share for the quarter. The consensus estimate for Rapport Therapeutics' current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for Rapport Therapeutics' Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($4.51) EPS, FY2027 earnings at ($6.80) EPS, FY2028 earnings at ($8.40) EPS, FY2029 earnings at ($8.08) EPS and FY2030 earnings at ($6.96) EPS.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Rapport Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. BTIG Research restated a "buy" rating and set a $65.00 price objective on shares of Rapport Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a report on Friday, July 17th. Leerink Partners began coverage on shares of Rapport Therapeutics in a research note on Wednesday, June 24th. They issued an "outperform" rating and a $52.00 target price for the company. Finally, Citigroup reiterated a "market outperform" rating on shares of Rapport Therapeutics in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Rapport Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.86.

Rapport Therapeutics Price Performance

RAPP stock opened at $45.49 on Monday. Rapport Therapeutics has a twelve month low of $13.86 and a twelve month high of $48.00. The stock's 50 day moving average is $39.77 and its 200-day moving average is $34.61. The firm has a market capitalization of $2.18 billion, a PE ratio of -14.96 and a beta of 0.97.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07).

Hedge Funds Weigh In On Rapport Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in Rapport Therapeutics in the first quarter worth about $30,000. Meeder Asset Management Inc. bought a new position in shares of Rapport Therapeutics during the 4th quarter valued at approximately $37,000. Russell Investments Group Ltd. bought a new position in shares of Rapport Therapeutics during the 3rd quarter valued at approximately $43,000. State of Wyoming purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter worth approximately $65,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Rapport Therapeutics by 64.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock worth $70,000 after purchasing an additional 905 shares during the last quarter.

Insiders Place Their Bets

In related news, CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction on Monday, July 27th. The stock was sold at an average price of $42.11, for a total transaction of $93,063.10. Following the sale, the chief executive officer directly owned 537,607 shares in the company, valued at approximately $22,638,630.77. This trade represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the company's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $40.05, for a total value of $743,808.60. Following the completion of the transaction, the insider owned 6,280,525 shares of the company's stock, valued at $251,535,026.25. This trade represents a 0.29% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 12.48% of the company's stock.

Trending Headlines about Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Neutral Sentiment: A recent analyst roundup provided additional coverage of Rapport Therapeutics, but the available report details did not disclose a specific new price target or recommendation for RAPP. Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and Honeywell Aerospace (HONA)
• Negative Sentiment: Wall Street Zen downgraded Rapport Therapeutics (RAPP) to “Sell,” creating a direct negative catalyst and potentially increasing selling pressure. Rapport Therapeutics NASDAQ: RAPP Downgraded by Wall Street Zen to Sell
• Negative Sentiment: HC Wainwright’s updated estimates project losses of approximately $4.51 per share in fiscal 2026, $6.80 in 2027, and $8.40 in 2028. Losses are forecast to narrow thereafter, but the firm still expects a $6.96-per-share loss in 2030. The 2026 estimate is also below the broader consensus loss forecast of $3.67 per share, signaling weaker-than-expected profitability prospects. HC Wainwright Earnings Estimates for Rapport Therapeutics

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source